Medline Industries recalled approximately 6.67 million alcohol prep pads on July 7, 2025. The recall stems from isopropyl alcohol levels falling below the labeled concentration. Consumers should stop using the product immediately and seek guidance from healthcare providers.
Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration.
Consumers and healthcare providers should stop using this product immediately. Contact MEDLINE INDUSTRIES, LP - Northfield or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Medline Alcohol Prep Pads, 70% Isopropyl Alcohol, sold in boxes of 100 sterile 2-ply pads. The model number is 61224040057. The pads were manufactured for Medline Industries, LP, and distributed nationwide.
The recall addresses a significant quality issue, as the isopropyl alcohol levels in the pads fall below the labeled concentration. This subpotent drug poses a risk as it may not effectively disinfect or prepare skin for injections.
No specific incidents or injuries have been reported related to this recall. However, the reduced efficacy of the pads could lead to inadequate disinfection, increasing the risk of infection.
Stop using the recalled alcohol prep pads immediately. Contact Medline Industries at 1-800-MEDLINE or consult your healthcare provider for further guidance.
For more information, visit www.medline.com or call 1-800-MEDLINE. Additional recall details are available at the FDA website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.